Latest news

• Lilly cuts 2021 guidance to reflect ‘lower expected revenue’ from COVID-19 antibody sales

  This increase can be attributed to Lily’s key growth products, including Trulicity, Verzenio, Olumiant, Tyvyt, Emgality, Jardiance, Retevmo, Cyramza and Taltz.

• Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

  The partnership complements Lilly’s existing focus on immuno-inflammatory diseases, led by drugs such as psoriasis therapy Taltz (ixekizumab), which has just had its indications extended to include paediatric patients,

• Lilly posts higher-than-expected profit as new drugs lift outlook

  Sales boosted by growth of Trulicity and Taltz. Eli Lilly has posted higher-than-expected profit on the back of increasing demand for its newly launched drugs, despite fighting continued price ... Sales of its psoriasis treatment Taltz(ixekizumab) also

• AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

  Cosentyx, Skyrizi and Tremfya face increasing competition in the psoriasis market however, with a host of other new entrants including Eli Lilly’s Taltz (ixekizumab), Leo/Valeant’s Siliq (brodalumab) and

• J&J splashes $750m on anti-inflammatory drug bermekimab

  As well as facing competition from Cosentyx and Skyrizi, Tremfya also has to contend with Eli Lilly’s IL-17 inhibitor Taltz (ixekizumab) and Pfizer’s oral JAK inhibitor Xeljanz (tofacitinib),